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Abstract: Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone re-
ceptor superfamily. Originally described as “orphan nuclear receptors”, they can bind both natural
and synthetic ligands acting as agonists or antagonists. In humans three subtypes, PPARα, β/δ,
γ, are encoded by different genes, show tissue-specific expression patterns, and contribute to the
regulation of lipid and carbohydrate metabolisms, of different cell functions, including proliferation,
death, differentiation, and of processes, as inflammation, angiogenesis, immune response. The PPAR
ability in increasing the expression of various antioxidant genes and decreasing the synthesis of
pro-inflammatory mediators, makes them be considered among the most important regulators of the
cellular response to oxidative stress conditions. Based on the multiplicity of physiological effects,
PPAR involvement in cancer development and progression has attracted great scientific interest
with the aim to describe changes occurring in their expression in cancer cells, and to investigate
the correlation with some characteristics of cancer phenotype, including increased proliferation,
decreased susceptibility to apoptosis, malignancy degree and onset of resistance to anticancer drugs.
This review focuses on mechanisms underlying the antioxidant and anti-inflammatory properties of
PPARs in physiological conditions, and on the reported beneficial effects of PPAR activation in cancer.
Keywords: peroxisome proliferator-activated receptors (PPARs); oxidative stress; cancer; inflammation
1. Introduction
The maintenance of intracellular redox homeostasis is crucial to ensure functionality
and survival of normal cells. Antioxidant defenses include several enzymes and molecules
responsible for the cellular response to oxidative stress. The expression of several of these
molecules is directly or indirectly regulated by transcription factors, including Peroxisome
Proliferator-Activated Receptors (PPARs). In this view, PPAR antioxidant properties have
been deeply investigated in both physiological and pathological conditions. This review
focuses on the mechanisms regulating PPAR expression and activity in normal cells, paying
particular attention on their involvement in controlling oxidative stress and inflammation.
Moreover, knowledge on the effects of PPAR-mediated modulation of oxidative stress in
cancer development and progression is also summarized.
2. PPAR Physiology
PPARs belong to nuclear hormone receptor superfamily and share characteristic
functional domains with other superfamily members. Originally described as “orphan
nuclear receptors”, PPARs are now known to bind a multitude of both natural and synthetic
ligands acting as agonists, antagonists, or inverse agonists [1–4]. Since several of these
ligands share the ability to induce, with different entity, peroxisome proliferation in rodent
hepatocytes, their receptors have been indicated as PPARs.
In humans three different subtypes, PPARα, β/δ, γ, are encoded by separate genes
and show tissue-specific expression patterns [5]. From PPARγ gene three different mRNA
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are transcribed (γ1, γ2, γ3) leading to the production of two proteins. All subtypes are
involved in the regulation of lipid and carbohydrate metabolisms (Table 1); moreover,
based on their expression in specific cell types or tissues, PPARs can play a pivotal role in
modulating different cell functions (proliferation, death, differentiation) [6], inflammatory
process [7], angiogenesis [8], immune response [9].
Table 1. Tissue distribution and functions of peroxisome proliferator-activated receptors (PPARs) in
lipid and carbohydrate metabolisms.
liver ↑ Oxidation of fatty acids,
ketogenesis, lipid homeostasis
heart ↑ Oxidation of fatty acids
↓ Glucose uptake
kidney ↑ Oxidation of fatty acids
PPARα
Refs. [10–12]
brown adipose tissue ↑ Oxidation of fatty acids
PPARβ/δ
Refs. [11,12]











skeletal muscle ↑ Insulin sensitization
The ligand-dependent biological effects of PPARs require their heterodimerization
with the nuclear receptor Retinoid X Receptor (RXR) and a conformational change that
determines co-repressor release and co-activator recruitment. In this activated form, the het-
erodimer PPAR/RXR binds to protein complexes, including histone acetyltransferase, and
to RNA polymerase II, this allowing chromatin remodeling, recruitment of transcription
machinery and transcription of target genes (trans-activation action) [14].
In these genes, the DNA-binding sequence of PPAR/RXR complex is called Peroxi-
some Proliferator Response Elements (PPRE) and consists of a direct repeat (DR-1) motif
composed of two half-sites that occur as a direct repetition of a hexanucleotide DNA se-
quence (AGGTCA) with a single nucleotide spacing between the two repeats. PPRE can be
located within promoter, or introns/exons or in 3′ downstream region of target genes [15].
The expression of PPARs has been recently evidenced to be epigenetically modulated
by a large number of miRNAs that target the different isoforms. This type of posttranscrip-
tional regulation has been characterized in different diseases in which the expression of
specific miRNA contributes to the pathogenesis, mainly through the downregulation of
PPARs [16–18]. In a recent review, Sundrani et al. [19] suggested that fatty acid-mediated
alterations in miRNAs/PPARs axis could be responsible for placental disorders leading
to babies with low birth weight. In a rat model of intestinal injury after hypoxia/re-
oxygenation, the increased expression of miR-23a-5p has been reported to further worsen
cell damage by decreasing PPARα and its antioxidant effect, this leading to an increased
ROS production [20].
The ability of miRNAs in modulating PPAR expression has also been evidenced for
the miRNAs delivered in the exosomes. In fact, miR-130a-3p, present in acinar cell-derived
exosomes, has been demonstrated to contribute to pancreatic fibrosis onset by decreasing
the PPARγ activity in stellate cells by directly binding to the PPAR-3′UTR [21]. miRNAs
targeting both PPARγ and δ have been found to be hyper-expressed in macrophages
isolated from visceral adipose tissues of obese mouse and contribute to the induction of
insulin-resistance [22,23].
Other than in a direct way, miRNAs can also indirectly affect the PPAR expres-
sion/functions since several complexes regulating PPAR transcriptional activity
( co-activators and co-repressors) are in turn targeted by specific miRNAs [24–26].
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The importance of the axis miRNAs/PPARs in modulating different cell functions
was further confirmed by the observation that PPRE sequences are present in the promoter
of several miRNAs to indicate a mutual modulation [16].
As previously reported, the activity of PPARs is regulated at different levels: by several
molecules or multiprotein complexes that can act as co-activators or co-repressors, and by
different types of post-translational modifications.
PPAR co-activators are known to show different intrinsic biological activities. They
include: (1) some enzymes, as histone acetylases (CBP/p300 and steroid receptor coacti-
vator, SRC-1) and ATPases (Brg1 or Brm members of SWI/SNF complex), responsible for
chromatin remodelling; (2) proteins forming a bridge between the nuclear receptor and
the transcription initiation machinery (PPAR binding protein/thyroid receptor associated
protein 220, PBP/TRAP220) [27–30].
Peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC-1), origi-
nally identified as a specific co-activator of PPARγ and now known to modulate the activity
of several transcription factors, favours PPAR/RXR action recruiting other co-activators
provided with histone acetyltransferase activity, and induces RNA polymerase II action
directly interacting with the TRAP/DRIP [31–34].
PPARs can heterodimer with RXR also in the absence of ligands and in this form
the dimer remains tied to the co-repressor complexes, such as NCoR (Nuclear receptor
corepressor), SMRT (Silencing mediator of retinoid and thyroid hormone receptor) or
RIP140 (Receptor Interacting Protein 140). These complexes directly or indirectly recruit
histone deacetylases (HDACs) that repress gene transcription via modulation of chromatin
structure [35–37].
PPAR activity is also modulated by different types of post-translational modifications,
named PTM, that include phosphorylation, SUMOylation, ubiquitination and acetylation.
The studies examining this aspect of PPAR physiology have been mostly conducted on
PPARα and γ. This type of regulation is very articulated, since the PTM effects on PPAR
activity depend on various factors, as the PPAR isoform, the site of modifications, the
effector of PTM and the substrate availability.
The phosphorylation of PPARα and γ occurs at specific serine residues and can be
due to MAPK, CDK or GSKβ. PPARα phosphorylation in serine 12 and 21 by MAPK or
CDK7 is known to increase its activity possibly via improved recruitment of co-activators
and release of co-repressors; differently, the degradation of PPARα is favoured by GSKβ-
mediated phosphorylation at serine 73 [38]. With regard to PPARγ, the phosphorylation of
serine 112 determines a different effect (activation or repression) depending on the kinase
involved: the activity is increased in case of MAPK-mediated phosphorylation, whereas is
reduced in case of CDK7/9 involvement [39–42].
SUMOylation negatively regulates both PPARα and γ [43–45]. SUMOylation of
lysine 185 or 358 in PPARα decreases its activity in hepatic cell lines and in liver, mainly
through an increased binding to NCoR co-repressor [46,47]. In PPARγ, several putative
SUMOylation sites have been identified [48], but mainly the effects on serine 107 have been
extensively investigated [39,49]. The importance of PTM in regulating PPARγ activity has
been further confirmed by the observation that the phosphorylation at serine 112 seems to
favour the SUMOylation at lysine 107 [49,50], suggesting a possible interconnection among
the different PTM pathways.
Polyubiquitination of all PPAR isoforms causes a decrease of transcriptional activity
due to their proteasomal degradation [51–54].
PPARs, Inflammation and Oxidative Stress
All PPAR isoforms hare well known to possess anti-inflammatory activity that takes
place through different mechanisms that are summarized in the Table 2.
The ability of PPARs in decreasing the synthesis of pro-inflammatory mediators
in several pathological conditions and in inflammatory experimental models has been
partially attributed to the ligand-dependent [trans-repression of transcription factors,
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mainly NF-kB, AP-1 and STAT. NF-κB transcriptional activity is inhibited by a direct
interaction of all PPAR isoforms to its p65 component [55–58]. Other than by binding to the
ligands, the PPAR-p65 interaction seems to be also modulated by MAPK signalling since
ciglitazone induces MAP kinase-mediated phosphorylation of PPARγ, this leading to a
major inhibition of NF-kB [55].
PPARα ligands, fibrates and WY-14643, have been evidenced to further decrease
NF-kB pathway via modulation of the expression, stability or activity of the inhibitor
IkB-α, [56,59,60].
Table 2. Principal mechanisms responsible for the anti-inflammatory activity of PPARs.
Mechanism Characteristics/Effects Isoform References
Ligand-dependent
trans-repression activity
(1) independent from the binding to specific DNA
sequences
(2) based on the interaction between ligand-bound ppar
and components of other transcription factors (NFKB,
AP-1) or regulatory complexes (iNOS)
(3) based on the inhibition of kinases involved in the
activation of other transcription factors
α, β/δ, γ [61–68]
Modulation of inflammasoma
activity
(1) decreased expression of NLRP3, CASPASE 1, IL-1β,
IL-18
(2) decreased expression of TLR




(1) increased expression of anti-inflammatory miRNA
(miR-142-3p, miR-124)
γ [73,74]
Direct up-regulation of genes
with anti-inflammatory
properties.
(1) increased expression via binding to ppre in target
genes (HO-1, C3, PGlyRPs, IL-10, eNOS, UCP2)
α [75–78]
crosstalk with NRF2 (1) “ARE” Sequences Present in PPARγ promoter
(2) putative PPRE sequences IN Nrf2 gene
γ [79,80]
[81]
A direct protein-protein interaction is also responsible for the trans-repression of AP-1
activity; in fact, GST pull-down experiments carried out by Delerive et al. [81] evidenced a
binding of PPARα to the amino-termi nal domain of c-Jun.
The transcription of STAT5 target genes has been reported to be inhibited in a dose-
dependent way by PPARα and γ activation [82]. This observation evidenced a recip-
rocal negative regulation between PPAR and STAT pathways, since it was previously
demonstrated that STAT5b inhibits PPAR transcriptional activity by binding to ligand–
independent AF-1 domain in PPARs [83,84]. The lack of STAT5b inhibition evidenced in
case of PPARα lacking AF-1 confirmed the importance of this domain in STAT5b-PPAR
crosstalk. The ability of PPARs in reducing STAT pathway has also been confirmed by the
finding that in human macrophages PPARα and γ agonists decreased STAT-mediated trans-
activation without directly decreasing the DNA binding of these transcription factors [85].
More recently, the treatment with HuoXueTongFu Formula, a liquid herbal formula
used in traditional chinese medicine and possessing anti-inflammatory properties, has been
shown to prevent intraperitoneal adhesion occurring after abdominal surgery by modu-
lating cytokine production via PPARγ-mediated downregulation of SOCS3/JAK2/STAT1
pathway [86].
Over the past 20 years, the ability of PPARs in modulating inflammasome activity was
included among the mechanisms responsible for their anti-inflammatory properties. In
particular, the majority of the studies investigated PPARs as regulators of NLRP3, the most
studied inflammasome complex [74].
PPARγ activation via both natural and synthetic ligands,ω-3 polyunsaturated fatty
acids, (PUFA) and rosiglitazone, have been demonstrated to inhibit NLRP3 increased
transcription occurring in mice deficient for CGI-58, a co-activator of adipose triglyceride
lipase, administered with a lipid rich diet, and in LPS-treated murine Raw 264.7 cells [68,87].
The beneficial effect of Morin (3,5,7,2′,4′-pentahydroxyflavone), a natural flavonoid, on
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obesity induced by high-fat diet in rats has been ascribed to its binding to PPARα and the
consequent decrease of mRNA of the NLRP3 inflammasome complex that is overexpressed
in this pathological condition. Moreover, the PPARα activation positively affects fatty acid
catabolism improving lipid profile in liver. A similar effect, albeit to a lesser extent, has
been observed in the same experimental model after treatment with a mixture of EPA and
DHA (eicosapentaenoic and docosaexaenoic acid, respectively) [88]
The efficacy of rosiglitazone in reducing inflammation via modulation of NLRP3 has
been more recently confirmed in a model of radiation-induced acute intestinal injury and
in intestinal macrophages isolated from the same animals [69].
In a similar way, the anti-inflammatory activity showed by abscisic acid, a natural
phytohormone, in a murine model of allergic airway inflammation has been attributed to
its ability in increasing PPARγ expression and, in consequence, in inhibiting NLRP3 [89].
In a mouse model of NAFLD (Nonalcoholic fatty liver disease), GW501516, a specific
PPARβ/δ ligand, inhibited the activation of NLRP3, NLRP6, and NLRP10 and decreased
the production of pro-inflammatory molecules induced by high fat diet and LPS [90].
At the present, two mechanisms have been suggested as responsible for the PPARγ-
mediated modulation of inflammasome activity: a downregulation of the expression of
inflammasome components and a direct interaction between DBD domain of PPAR and
NLRP3, this interfering with NLRP3 assembly [69,91].
The crosstalk between PPARs and Nrf2 (NF-E2-related factor 2), has been evidenced
to play an important role not only in modulating inflammatory process, but also oxidative
stress. Nrf2 is considered as one of the most important regulator of cellular response to
oxidative stress [92–94] and of xenobiotic metabolism, via binding to Antioxidant Response
Element (ARE) in the promoter of target genes. The anti-inflammatory action of Nrf2 is
mainly due to its ability in modulating several pathways and determining: (1) inhibition of
NF-kB transcriptional activity via competition with co-activator CBP [95–97]; (2) inhibition
of the expression of cytokines TNFα, IL-6, IL-1β, and of COX and iNoS [98–100].
The involvement of both Nrf2 and PPARs in modulating inflammatory process sug-
gested the possibility of a mutual control of the expression of these transcription factors.
This hypothesis has been directly confirmed by the observations that two ARE are present
in PPARγ promoter [78,79] and a putative PPRE is present in Nrf2 promoter region [101].
Based on these observations several studies investigated the possibility to improve the regu-
lation of inflammation process by acting simultaneously on PPAR and Nrf2 pathways. With
this aim, the effects of specific Nrf2 or PPAR activators, or dual agonists have been investi-
gated in both in vivo and in vitro models of different diseases characterized by increased
inflammation and oxidative stress. The results evidenced, in most cases, greater beneficial
outcomes and confirmed the significant crosstalk between PPARs and Nrf2 [102–104]. This
last aspect has been further underlined by the observation that the promoter of some genes,
as glutathione transferase, contains both ARE and PPRE sequences [101].
PPAR anti-inflammatory properties also contribute, in an indirect way, to their ability
in acting as regulator of cellular response to oxidative stress. As a whole, the antioxidant
activity of PPARs is mainly due to their ability in directly activating the transcription of
genes showing antioxidant activity, in modulating at post-transcriptional level the activity
of proteins with antioxidant functions, or negatively affecting the expression/activity of
proteins generating or metabolizing free radicals.
Table 3 summarises genes containing PPRE in their promoter region, as evidenced by
bioinformatic approach or reporter gene assay.
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Table 3. Main antioxidant genes under transcriptional control of PPARs.
Gene Function Species References
Catalase Decomposition of H2O2 Human, mouse, rat [105–107]
Heme Oxygenase-1 Induction of DNA binding activities of transcription
factors involved in response to oxidative stress.
Mouse [108,109]
Glutathione Peroxidase 3 Reduction of hydrogen peroxide and related lipid
hydroperoxides.
Human [110]
Superoxide Dismutase Conversion of two superoxide anions to oxygen and
hydrogen peroxide
Mouse [111]
Thioredoxin Redox active protein containing two cysteine
residues
Human [112]
CD36 Scavenger receptor for oxidized lipids Human [113]
Uncoupling Protein Modulation of free radical production in
mitochondria
Rat [114–116]
The presence of the PPAR DNA-binding sequence in genes under transcriptional
control of PPARs has been previously suggested by studies using specific ligands for the
different PPAR isoforms, knockout animals or silencing technique.
The researches on this topic deeply investigated the correlation between PPARγ and
catalase expression, evidencing that this isoform prevents, via catalase induction, the
oxidative stress associated with different conditions, as apoptosis induction [117], pesti-
cide inhalation [118], LPS-induced brain impairment [119], hypertension [120], calcium
oxalate-induced nephrolithiasis [114]. This antioxidant effect has been observed using
canonical synthetic PPARγ agonists (pioglitazone, rosiglitazone) [119,121], natural lig-
ands, as catalpol [122] or a combination of synthetic and natural ones (carvacrol plus
pioglitazone [118].
In a similar way, PPARα agonist fenofibrate has been recently reported to reduce
oxidative stress through the increased expression of catalase in cultured rat cardiomiocytes
exposed to high glucose uptake or hypoxia/reperfusion condition [123]. The fenofibrate-
mediated increase of catalase expression, and the consequent improvement of redox state,
also occurred in testicular tissue of diabetic rats [124].
PPARβ/δ has been evidenced to play a crucial role in maintaining function and
characteristics of vascular endothelium in in vivo and in vitro studies through its ability in
modulating the expression of antioxidant enzymes, including catalase.
In a rat model of ischemia/reperfusion PPARβ/δ activation with the specific ligand
GW0742 upregulated catalase, UCP-3 and superoxide dismutase 2 (SOD2) [125]. The con-
sequent reduction of oxidative stress has been demonstrated by the decreased production
of 4-hydroxy-2-nonenal (HNE), the major lipid peroxidation product, and of formation
of its adducts with proteins. Interestingly, this research also evidenced that PPARβ/δ
increased at transcription level the expression of aldehyde dehydrogenase 2 (ALDH2), the
mitochondrial isoenzyme of ALDH known to metabolize acetaldehyde and HNE derived
from lipid peroxidation [126,127]. This observation indicates that PPAR modulation of
oxidative stress is also due to their ability in favouring the metabolism of highly reactive
aldehydic products of lipid peroxidation.
As in the case of catalase, also SOD expression is directly increased by ligands of all
PPAR isoforms. This contributes to the beneficial effects of these molecules reported in
different pathological conditions characterized by oxidative stress, including oxidative
damage of pancreatic cells and atrial remodelling in diabetes [128,129], intervertebral disc
degeneration responsible for of back and neck pain [130], benign prostatic hyperplasia [131].
An important crosstalk involved in intracellular defence against oxidative and in-
flammatory conditions concerns PPARs and heme oxygenase (HO), mainly HO-1. All
PPAR isoforms have been reported to induce the expression of HO-1 [132]. PPAR-mediated
expression of HO-1 contributes in preserving/improving vascular integrity in different
conditions of vascular disorders, as angiotensin II-induced hypertension in rats [133,134]
and pulmonary hypertension due to proliferation of smooth muscle cells [135]. In iron-
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challenged hepatocytes, the adiponectin-mediated activation of axis PPAR/HO-1 decreases
apoptotic cell death and iron accumulation, reducing the clinical hepatic consequence
of iron overload [136]. A similar protective effect due to PPARγ and HO-1 overexpres-
sion/activation has been described in an animal models of fibrotic steatohepatitis [137] and
in renal damage consequent to ischemia/reperfusion [138]. The ability of HO in influencing
in turn PPAR activity has been documented by the observation that in macrophages and
muscle cells carbon monoxide produced by HO-1 activity is able to increase PPARγ and
β/δ, this leading to beneficial effect through the modulation of different signalling trans-
duction pathways, including inhibition of early growth response-1 (Egr-1) and activation
of ERK5 [139–142].
Uncoupling proteins (UCPs) contribute to the maintenance of intracellular redox
homeostasis by decreasing the ROS production in mitochondria [143]. In this view, the
regulation at transcriptional level of their expression by PPARs represents an important
mechanism contributing to cellular defence toward oxidative stress. The first studies on
this aspect of PPAR antioxidant activity mainly investigated the effect of PPARα and γ
ligands on the expression and activity of the three UCP isoforms. Teruel’s group evidenced
that in rat brown adipocytes rosiglitazone increased UCP-3 and UCP-1, and WY14643
increased UCP-3, also suggesting a possible synergic or competitive effect of contempo-
rary administration of both ligands depending on the specific UCP isoform [114,115,144].
Transcriptional upregulation of UCP-2 induced by rosiglitazone protects against oxidative
stress in rostral ventrolateral medulla, preserving the activity of premotor neurons respon-
sible for the maintenance of neurogenic vasomotor tone, and reducing hypertension [145].
More recently, PPARβ/δ specific ligand GW0742 has been shown to relieve endothelial
alterations induced by LPS via upregulation of UCP-2 and the consequent reduction of
intra-mitochondrial ROS production [146].
3. PPARs and Oxidative Stress in Cancer
Based on the multiplicity of physiological effects above-described, PPAR involvement
in cancer development and progression has attracted great scientific interest.
The main observation emerged from the studies is that a wide species specificity
characterizes the effects of the activation of different PPAR isoforms on carcinogenesis
process.
The species specificity of PPAR effects has been above all documented for PPARα
whose activation, by natural or synthetic ligands, resulted associated with hepatocarcinoma
occurrence in rodents, and not in other species. In sensitive species, PPARα activation
seems to drive liver carcinogenesis through several mechanisms, including increase of
cell proliferation via activation of c-Myc and cyclins, decrease of susceptibility to undergo
apoptosis, increase of oxidative stress [147–149]. This last event seems to be triggered by the
PPARα-mediated increase of enzymes showing oxidase activity and different subcellular
localisation, as in peroxisome, endoplamatic reticulum, and mitochondria.
In particular, acyl-CoA oxidase (ACO) [150], NADPH oxidase [151,152] and cy-
tochrome P4504A1 [153] have been indicated as responsible for the increased ROS produc-
tion contributing to the initiation phase of carcinogenic process in murine liver. In the same
animals, a PPARα-mediated energy burning in liver has been also indicated as a factor
contributing to hepatocarcinogenesis [154].
In the various species, the different ability of PPARα ligands in inducing ROS forma-
tion has been related with a different basal expression level present in the hepatocytes. In
particular, in human liver, a low level of PPARαmRNA and protein has been reported [155],
even if this observation has not been confirmed in a study comparing the consequences
of PPARα activation in cultured human and rodent hepatocytes, and suggesting a major
effect of PPARα [156]. Other than to the low expression level, a different sequence in
ligand-binding domain (LBD) of PPARα could decrease the response to the same ligand
concentrations in primates and humans and, in consequence, their susceptibility to undergo
carcinogenesis process.
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With regard to the changes occurring in cancers and cultured cancer cells, both increase
or decrease of PPAR expression have been reported (Table 4). Anyway, the alterations in
the activity of these nuclear receptors always significant contribute to the acquisition of
cancer phenotype.
Table 4. PPAR expression in some cancers in comparison with corresponding normal cells/tissues.




























Lung Cancer(mouse model) Decrease [167]
β/δ Prostate Carcinoma
(human specimens;
DU145, PC3, LNCAP, VCAP, C4-2, 22RV1 cell lines)
Decrease [168]
Melanoma
(human specimens; A375 cell line)
Increase [169]
NSCLC











The different trend in PPAR expression evidenced in various types of tumours could
be related to the activity levels present in the corresponding normal cells or to the tissue-
specific functions played by each isoform. Interestingly, a correlation between PPAR
expression and malignancy degree have been observed in some tumours, this further
underlying the pivotal role played by PPARs also in cancer progression and suggesting
the possibility to different affect cancer cells with different malignancy degree using PPAR
ligands [163].
In this view, conjugated linoleic acid (CLA) has been shown to be more effective
against cancer cells with higher malignancy degree and originated from different tissues.
Moreover, the kind of effect was dependent on the different modulation of PPAR isoforms.
In fact, the contemporary increase of PPARα and decrease of PPARβ/δwas associated with
the induction of apoptotic death, whereas PPARγ activation with the inhibition of cell pro-
liferation [63]. These results have been confirmed in human hepatocarcinoma HepG2 cells
where the specific PPARα agonist clofibrate caused apoptosis in a time- and concentration-
dependent way, and PGJ2, a ligand of PPARγ, inhibited cell proliferation [173]. In rat
hepatoma cell lines exposed to high clofibrate concentrations capable of also activating
PPARγ, the inhibition of proliferation was mediated by the increase of protein phosphatase
2A and the consequent decrease of Erk1,2 and c-myc [174]. The increased expression
of PP2A has been later attributed to the presence of putative PPRE sequences in genes
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encoding its subunits [175]. In human hepatocellular carcinoma HepG2 and in colorectal
adenocarcinoma CaCo2 cells, the concurrent administration of PPARα ligand clofibrate
and of JNK inhibitor AS60012145 reduced proliferation and induced apoptosis, likely via
the overexpression of 28 genes containing PPRE [176]. PPAR ligands have been shown to
reduce cancer cell growth also acting synergistically with HNE [177,178].
The anticancer effect of PPARs is also due to their ability in modulating oxidative
stress, through the effect on the expression of antioxidant enzymes, the induction of lipid
peroxidation and the activity of enzymes metabolizing the lipid peroxidation products.
These effects have been observed using both natural or synthetic ligands of the
different isoforms.
With regard to the involvement of PPAR activation in early stages of carcinogenesis
process, the beneficial reported effects can be mainly referred to the prevention of oxidative
stress associated with tumoral cell transformation.
In animal experimental models of lung cancer, oral administration of rosiglitazone
resulted in an increase of GPx expression and glutathione content, and in a decreased of
malondialdeyde (MDA) production, this blocking the diethylnitrosamine-induced cancer
formation [179]. In a similar way, Balupillai and coll. [180] demonstrated that the induction
of photocarcinogenesis in mice skin was prevented by caffeic acid probably through the
activation of PPARγ and the improvement of oxidative imbalance induced by UVB. Ly-
copene, a natural carotenoid known to prevent the development of several types of cancers,
has been shown to activate PPARγ in esophageal cancer cell line EC109, and to inhibit, at
appropriate doses, the esophageal carcinogenesis induced by methylbenzylnitrosamine in
rat, via the reduction of oxidative stress-mediate MDA formation and of pro-inflammatory
cytokine level [181,182].
Studies on cultured tumour cells, derived from different tissues, evidenced that the
anticancer effect of PPARs can occur also through the modulation of different signalling
pathways and the induction of oxidative stress causing a cytostatic or cytotoxic effect.
Arachidonic acid, a natural ligand of PPARs, caused suppression of growth of lung
cancer cells A549, through the increase of PPARγ and lipid peroxidation. In this cells
the known cytostatic effect of lipid peroxidation products [183] was augmented by the
decreased expression of cytosolic ALDH3, the main responsible for the catabolism of
aldehydes derived from PUFA oxidative breakdown. The reduction of ALDH3 expression
has been demonstrated to be due to the PPAR-mediated inhibition of NF-kB, for which
several consensus sequences are present in the ALDH gene [184].
In lung cancer cells A427, both n-3 and n-6 PUFA increased PPARα expression and
lipid peroxidation, and inhibited cell proliferation [185]. In this research, a putative PPRE
has been evidenced in genes encoding the fast isoforms of myosin heavy chain, which
suggested the PPAR activation as possible therapeutic approach against cancer cachexia.
To be noted that treating cancer cells with PUFA is motivated by the fact that carcinogenetic
process is associated with a reduced PUFA amount in membrane phospholipids, this
contributing to their decreased susceptibility to undergo lipid peroxidation [186,187].
The cytostatic effect of PPARs has been evidenced also by Srivastava and coll. [188] in
lung adenocarcinoma cells NCI-H2347 and NCI-H1993, where an alternative pathway of
PPAR-mediated cell growth inhibition has been documented. In fact, in this experimental
model, the PPARγ activation by pioglitazione caused a metabolic switch consisting in
a decrease of pyruvate oxidation and GSH level. In turn, the decreased intracellular
antioxidant defence augmented ROS production determining the hypophosphorylation of
retinoblastoma protein and the block of cell cycle.
Using a multi-tiered approach, Savic and coll. [189] confirmed in human colon cancer
cells HT-29 that PPARγ activation decreases proliferation through the increase of lipid
peroxidation consequent to the GSH reduction.
A mutual influence among PPAR isoforms has been observed in human squamous
carcinoma cells SCC-15, where silencing PPARγ caused an increase of PPARα and β
mRNA [190]. The authors suggested the possibility that PPARγ negatively regulates the
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expression of other PPARs. This finding could be important in designing new therapeutic
approaches aiming to differently affect various PPARs in cancers.
An important event reducing the efficacy of anticancer therapies is the onset of cancer
cell resistance to chemotherapeutic drugs, that can be due to several mechanisms, including
the increase of antioxidant defences and drug transporter proteins, decrease of detoxifying
enzymes or susceptibility to apoptosis.
The above-reported ability of PPARs in modulating ALDH expression, confirmed also
in rat hepatoma cells and human breast cancer cells [191,192], can represent a strategy to
reduce the resistance to anticancer drugs acting through the formation of free radicals,
as doxorubicin, or oxazaphosphorines, whose metabolic intermediates are catabolized
by ALDH [193]. It is important underlying that in several type of cancers the expression
of ALDH1 and ALDH3 is constitutively increased and contributes to their decreased
susceptibility to the effects of lipid peroxidation products. [194].
Superparamagnetic iron oxide nanoparticles (SPIONs) functionalized with CLA for
theranostics use, other than to inhibit breast cancer cell growth via PPARγ activation, also
decreased the expression of P-glycoprotein, a drug efflux transporter. This effect is probably
the consequence of PPAR-mediated induction of necrosis, increase of TNFα and IL-1β,
cytokines known to inhibit P-glycoprotein expression [192,195].
In gastrointestinal cancer cells, the cisplatin resistance, characterized by increased
expression of aldo-keto reductase 1B10 (AKR1B10), an enzyme associated with resistance)
against anticancer drugs and decreased PPARγ, is reverted by a combined treatment with
a AKR1B10 inhibitor and rosiglitazone [196]. The onset of resistance to cisplatin reduces
the therapy efficacy also against brain cancers. Human glioma cells U-87 overexpressing
PPARγ showed a decreased production of P-glycoprotein, increased oxidative stress and
sensitivity to cisplatin in comparison with parenteral ones [197].
The importance of PPARs in preventing the chemoresistance occurrence has been
confirmed in non-small cell lung cancers (NSCLC) where hypoxia, via HIF-1, has been evi-
denced to contribute to the resistance to cisplatin or docetaxel. The mechanisms responsible
seems to be the inhibition of PPARγ, the decrease of UCP-2, and the consequent ROS-
induced expression of ABC transporter protein ABCG2, which causes drug efflux [198].
In the same type of cancer cells, CB13 (1-benzyl-5-(4-methylphenyl) pyrido [2,3-
d]pyrimidine-2,4(1H,3H)-dione), a recently synthesized PPARγ ligand, reduces the radio-
resistance via the production of ROS and induced apoptosis through the stimulation of
caspase-3, and caspase-9 activities [199].
Since the adaptive increase of antioxidant defences in cancers represents an important
factor in inducing chemoresistance, several studies evidenced that a constitutive activation
of Nrf2, due to increased expression or mutations in Nrf2 or its inhibitor KEAP1, contributes
to the resistance to therapy in various types of cancers [200].
In this view, the above-reported crosstalk between PPARs and Nrf2 could represent
an important target to increase cancer sensibility to chemotherapeutics. This possibility has
been indirectly investigated by Zhan and coll. [201] in NSCLC cell lines knockdown for
KEAP1, the Nrf2 inhibitor. In these cells, the moderate increase of Nrf2 level was associated
with the increase of PPARγ and sensibility to cytotoxic effect of arsenic trioxide (As(2)O(3)),
etoposide, and doxorubicin.
Recently, another beneficial effect of PPARγ/Nrf2 activation in cancer cells has been
reported in a rat model of paclitaxel-induced neuropathic pain Rosiglitazone has been
shown to revert the downregulation of PPARγ occurring in the spinal cord of rats showing
paclitaxel-induced neuropathic pain, and reduce the pain, probably through the increased
expression of Nrf2/HO-1 [103].
4. Conclusions
Starting from their classification as members of Nuclear Receptor superfamily, PPARs
have been the subject of increasing scientific interest and studies leading to the characterisa-
tion of the roles played by the three isoforms in modulating different cell metabolisms and
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functions in normal cells. Based on the multiplicity of their physiological activities, PPARs
have been demonstrated to be able to influence the different phases of carcinogenic process
and some cancer cell characteristics, including growth, death, invasivity and resistance to
anticancer therapy.
The fact that PPAR ligands include a wide variety of natural substances, as dietary
fatty acids and natural antioxidants, makes PPAR activation an attractive and more save
approach to selectively target cancer cells.
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